A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research sub-study is to learn about the levels of an antiretroviral
(ARV) medication called Raltegravir, and response to HIV virus in the genital tract of
HIV-positive women.
We would like to see how this study medication is tolerated, and how the body processes the
study medication in women who are HIV-positive. More specifically, we are interested in how
Isentress® might penetrate into the female cervicovaginal secretions thereby potentially
reducing the amount of HIV in those secretions. A reduction in the amount of HIV in genital
secretions may prevent female subjects from transmitting HIV to their sexual partners. This
information will help the research team know how a medication such as Isentress® might be
used to prevent the sexual transmission of HIV.